The molecular basis of beta-thalassaemia
intermedia in southern China: genotypic heterogeneity and phenotypic diversity.
GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia
. Eur J Endocrinol 1998;138:394-400.
Prevalence of endocrine complications in beta-thalassaemia
major in the Islamic Republic of Iran.
intermedia: Is it possible consistently to predict phenotype from genotype?
Increased plasma levels of interleukin-6 and interleukin-8 in beta-thalassaemia
Prevalence and genotypes of alpha-and beta-thalassaemia
carriers in Hong Kong-implications for population screening.
Evaluation of the diagnostic reliability of different RBC indices and formulas in the differentiation of the beta-thalassaemia
minor from iron deficiency in Palestinian population.
SAFE: The study says gene therapy for patients with beta-thalassaemia
can be safe.
Both parties will collaborate to develop EPI01 in sickle cell disease and beta-thalassaemia
. EpiDestiny retains all rights to continue development of EPI01 in oncology.
The triplicated alpha-globin gene locus in beta-thalassaemia
heterozygotes: clinical, haematological, biosynthetic and molecular studies.
Epidemiology of Transfusion Transmitted Infection among Patients with beta-Thalassaemia
Major in Pakistan.
The first report of the Crispr/Cas9 technique being applied to human embryos (http://www.ibtimes.com/worlds-first-genetically-modified-human-embryo-created-chinese-scientists-claim-new-1893752) emerged in April 2015 , when a team of Chinese scientists showed - through a partially successful experiment - that errors in the DNA that cause beta-thalassaemia
, a life-threatening blood disorder, could be corrected through gene modification in early stage embryos.